Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
134 results about "Memory retention disorder" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Memory disorder. Memory disorders are the result of damage to neuroanatomical structures that hinders the storage, retention and recollection of memories. Memory disorders can be progressive, including Alzheimer's disease, or they can be immediate including disorders resulting from head injury.
Multiple lead method for deep brain stimulation
ActiveUS20080103547A1Easy to controlGood treatment effectHead electrodesExternal electrodesDiseaseThalamus
New methods for deep brain stimulation (DBS) surgery using two or more electrical leads are provided. The methods are useful for treating a wide variety of brain-associated disorders including movement-related disorders, psychiatric disorders, metabolic / eating disorders, memory disorders, and pain. Methods featuring stimulation of distinct target areas of a subject's brain, such as the thalamic ventralis intermedius (VIM) and the ventralis oralis (VOA / VOP) using multiple electrical leads for treatment of tremor provide superior clinical outcomes to stimulation with single leads implanted in these target areas.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Compositions and methods for improving or preserving brain function
InactiveUS20070179197A1Improve performancePrevent and reduce delayBiocideNervous disorderRegimenExercise performance
The present invention is related to mammalian nutrition and effects thereof in individuals with age associated cognitive decline such as Age Associated Memory Inpairment (AAMI) or a dementing illness such as Alzheimer's disease or related dementia, or Mild Cognitive Impairment, such as improving performance in, or reversal, prevention, reducing and delaying decline in, one or more of cognitive function, memory, behavior, cerebrovascular function, motor function, and / or brain physiology are seen. In particular, the present invention utilizes medium chain triglycerides, in one embodiment, administered as part of a long-term treatment regimen, to preserve or improve learning, attention, motor performance, cerebrovascular function, social behavior, and to increase activity levels, particularly in aging mammals.
Owner:ACCERA INC
Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
InactiveUS20060094783A1Avoid nerve damageBiocideOrganic active ingredientsMemory disorderAttention deficits
The subject invention provides methods of treating a subject afflicted with Parkinson's disease, memory disorder, depression, hyperactive syndrome, Attention Deficit Disorder, dementia, brain ischemia, stroke, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, multiple sclerosis, nerve damage, affective illness, schizophrenia or symptoms of withdrawal from an addictive substance, using the mesylate salt of R(+)-N-propargyl-1-aminoindan.
Owner:TEVA PHARMA IND LTD +1
Use of ketogenic compounds for treatment of age-associated memory impairment
InactiveUS8124589B2Prevention of loss of cognitive functionLower metabolismBiocideNervous disorderMemory disorderTG - Triglyceride
Owner:CERECIN INC
Carboxylic acid compound cyclopropane ring
InactiveUS20050075393A1Lower metabolismSmooth transmissionBiocideNervous disorderSynapseMemory disorder
A carboxylic acid compound having cyclopropane ring(s) of the formula (I): wherein R is alkyl or alkenyl optionally having one or more 1,2-cyclopropylene in a carbon chain and / or optionally having cyclopropyl at the end of a chain, X is a single bond or alkylene, wherein the total number of carbon less the number of cyclopropane ring is 10-25, and a pharmaceutically acceptable salt thereof are provided. The compound (I) shows an LTP-like potentiation of synaptic transmission, allows slow metabolism in the living body, shows a stable LTP-like potentiation of synaptic transmission, and is useful as an agent for LTP-like potentiation of synaptic transmission, a cognition-enhancing drug or an agent for the prophylaxis and treatment of dementia, a learning and memory disorder and a neurotransmitter release disorder.
Owner:NISHIZAKI BIOINFORMATION RES INST +1
Peptide compositions with effects on blood glucose
InactiveUS20050222036A1Strengthen associationEnhance spatial learningPeptide/protein ingredientsMetabolism disorderDiseaseMemory retention
The present invention provides compositions and methods for ameliorating neurological or memory disorders and improving learning and cognition through the increase of cyclic AMP. Gilatides, peptides comprising the nine amino acid sequence (SEQ ID NO:1), and functional analogs thereof are disclosed to modulate neurological activity when administered to a subject. The methods of the invention can be used to prevent or treat neurological disorders as well as improve memory retention and acquisition. In addition, the invention can be used to modulate insulin levels and blood glucose. The invention includes pharmaceutical compositions comprising a therapeutically or prophylactically effective amount of a Gilatide peptide or a functional analog thereof.
Owner:THOMAS JEFFERSON UNIV
Therapeutic agents useful for treating pain
A Compound of formula (wherein X is O or S and R<1>-R<5 >are disclosed herein) or a pharmaceutically acceptable salt thereof (each being a "Piperazine Compound"), pharmaceutical compositions comprising a Piperazine Compound and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperazine Compound are disclosed.
Owner:PURDUE PHARMA LP
Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
The invention relates to compounds of the general formula (I): whereinAr is optionally substituted aryl or heteroaryl;A is (i) —O—, —S—, —SO2—, —NH—, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and / or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members;B is —C(R4)(R5)—, —OC(R4)(R5)—, —N(R6)C(R4)(R5)—, —N(R6)—, —O—, —S— or —SO2—;R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl;R1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R4)(R5)]xN(R2a)(R3a)];R2a, R3a, R4, R5, R6 and x are as defined in the claims, and n is 0 or 1; and pharmaceutically acceptable salts, hydrates and prodrug forms thereof.The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders. The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I).
Owner:PROMIMAGEN LTD +1
Amyloid beta protein (globular assembly and uses thereof)
The invention provides amyloid beta-derived dementing ligands (ADDLs) that comprise amyloid β protein assembled into globular non-fibrillar oligomeric structures capable of activating specific cellular processes. The invention also provides methods for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDLs, and modulating ADDL formation and / or activity, inter alia in the treatment of learning and / or memory disorders.
Owner:NORTHWESTERN UNIV & THE UNIV OF SOUTHERN CALIFORNIA
Medical application of protopanaxatriol and protopanaxadiol in nervous system diseases
The invention relates to medical application of protopanaxa-triol (PPT), protopanaxadiol (PPD) and mixtures of the PPT and the PPD in any proportion in nervous system diseases, which are preferably used for treating and / or preventing epilepsy, cerebral ischemic diseases, memory disorder and parkinsonism syndrome.
Owner:王泽君
Combination of atypical antipsychotics and 5HT-1B receptor antagonists
InactiveUS20050256112A1Reduce morbidityDifferent recognizableNervous disorderMetabolism disorderDiseaseHeadaches
The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof, (ii) a 5-HT1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.
Owner:PFIZER INC
Therapeutic agents useful for treating pain
ActiveUS20040106625A1Avoid adjustmentOrganic active ingredientsBiocidePreventing painInflammatory Bowel Diseases
A compound of formula: wherein A, Ar, R<3>, R<6>, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a "Cyanoiminopiperazine Compound"), compositions comprising an effective amount of a Cyanoiminopiperazine Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cyanoiminopiperazine Compound are disclosed.
Owner:PURDUE PHARMA LP
Insulin-associated peptides with effects on cerebral health
InactiveUS7655619B2Efficiently enter brainImprove performanceNervous disorderCell receptors/surface-antigens/surface-determinantsMemory retentionInsulin A Chain
The present invention provides compositions and methods for ameliorating neurological, attention, or memory disorders and improving learning and cognition through the delivery of insulin A-chain and analogs thereof to a subject. Insulin A-chain, peptides comprising the 21 amino acid sequence GIVEQ CCASV CSLYQ LENYC N (SEQ ID NO:1), and functional analogs thereof are disclosed to modulate neurological activity when administered to a subject. The methods of the invention can be used to prevent or treat neurological disorders as well as improve memory retention and acquisition. The invention includes pharmaceutical compositions comprising a therapeutically or prophylactically effective amount of insulin A-chain peptide or a functional analogs thereof.
Owner:THOMAS JEFFERSON UNIV
Memory in subjects with mini-mental state examination of 24-26
InactiveUS20100331258A1Reduce needReduce dosage of treatmentBiocideNervous disorderDocosahexaenoic acidModerate dementia
The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and / or eicosapentaenoic acid, for improving memory and / or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20-26, the memory impairment in the sub-group of 24-26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup.
Owner:NUTRICIA
Di-substituted amides for enhancing glutamatergic synaptic responses
InactiveUS8013003B2Stable baselineIncrease amplitudeBiocideNervous disorderSIDS - Sudden infant death syndromeCentral sleep apnea
Owner:CORTEX PHARMA INC
Novel piperidine derivative
Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.
Owner:MSD KK
Memory assessment by retrieval speed and uses thereof
The present invention provides methods for assessing episodic memory in a subject. Also provided are methods for assessing semantic memory in a subject. The present invention further provides methods for screening for an agent directed to treating, slowing down the progress of, attenuating the symptoms of, or preventing dementia characterized by episodic memory impairment. Additionally, the present invention provides methods for screening for an agent directed to treating, slowing down the progress of, attenuating the symptoms of, or preventing dementia characterized by semantic memory impairment. Finally, the present invention provides methods for measuring semantic memory in a subject.
Owner:ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV
Tuckahoe extract and preparation method thereof
ActiveCN102133242AEnrichmentReduce errorsNervous disorderPlant ingredientsMemory disorderMemory retention disorder
The invention discloses a tuckahoe extract which is prepared through ethanol extraction and macroporous absorption resin purification. The tuckahoe extract enriches more effective parts. Moreover, a rat memory disorder model test proves that the tuckahoe extract can improve the learning and memory capacity of a model rat, so that the number of errors of the model rat is reduced and the latent period is prolonged.
Owner:BEIJING UNIV OF CHINESE MEDICINE
Composition comprising minocycline as an effective component for prevention and treatment of dementia, and learning and memory impairments
InactiveUS20060148766A1Avoid cell deathAvoid cytotoxicityBiocideTetracycline active ingredientsMemory disorderBULK ACTIVE INGREDIENT
The present invention relates to a composition for preventing and treating dementia and memory impairment, which contains minocycline as active ingredient. The composition of the present invention has an effect of inhibiting brain cell death and memory impairment, which are induced by amyloid beta-protein and C-terminal protein. Thus, the composition of the present invention is useful for the prevention and treatment of various dementias, including Alzheimer's disease, and the impairment of learning and memory and cognitive function.
Owner:SUH YOO HUN +4
Agent for improving nervous system cell functions
InactiveUS20090246186A1Improve and prevent central neurological diseaseImprove cell functionSenses disorderNervous disorderDiseaseNervous system
The present invention aims to activate neural cells in brain, and further provide a useful composition having an action to protect intracerebral neural cells from external and internal stresses.An agent for improving a neural cell function containing reduced coenzyme Q as an active ingredient, more specifically, an agent for activating neural cells and an agent for protecting neural cells, is useful, and can be used for the improvement or prophylaxis of central neurological diseases or neuropathy symptoms derived from or associated with a neurodegenerative disease, promotion of cognitive function or improvement of learning and memory disorders.
Owner:KANEKA CORP
Permeability nose absorption type medicine for treating and preventing senile dementia, improving learning memory faculty and regulating blood brain barrier
InactiveCN1861060AEasy to controlPromote recoveryOrganic active ingredientsNervous disorderNoseEugenol
A snuff for preventing and treating senile dementia, improving memory and regulating the permeability of blood brain barrier is prepared from the active component(s) chosen from eugenol, its salt, its isomer and their mixture, and selective natural spice.
Owner:李光武
Carboxylic acid compound having cyclopropane ring
A carboxylic acid compound having cyclopropane ring(s) of the formula (I): wherein R is alkyl or alkenyl optionally having one or more 1,2-cyclopropylene in a carbon chain and / or optionally having cyclopropyl at the end of a chain,X is a single bond or alkylene, wherein the total number of carbon less the number of cyclopropane ring is 10-25, and a pharmaceutically acceptable salt thereof are provided. The compound (I) shows an LTP-like potentiation of synaptic transmission, allows slow metabolism in the living body, show a stable LTP-like potentiation of synaptic transmission, and is useful as an agent for LTP-like potentiation of synaptic transmission, a cognition-enhancing drug or an agent for the prophylaxis and treatment of dementia, a learning and memory disorder and a neurotransmitter release disorder.
Owner:NISHIZAKI BIOINFORMATION RES INST +1
Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
The invention relates to compounds of the general formula (I):whereinAr is optionally substituted aryl or heteroaryl;A is (i) —O—, —S—, —SO2—, —NH—, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and / or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members;B is —C(R4)(R5)—, —OC(R4)(R5)—, —N(R6)C(R4)(R5)—, —N(R6)—, —O—, —S— or —SO2—;R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl;R1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R4)(R5)]xN(R2a)(R3a)];R2a, R3a, R4, R5, R6 and x are as defined in the claims, and n is 0 or 1; and pharmaceutically acceptable salts, hydrates and prodrug forms thereof.The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I).
Owner:PROMIMAGEN LTD +1
Pyrrolidine derivatives for vision and memory disorders
This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using pyrrolidine derivatives.
Owner:GPI NIL HLDG INC +1
Method of treating cognitive deficits in learning and memory
InactiveUS6979698B1Improve memory functionImprove Medication AdherenceBiocideAnimal repellantsPartial Nicotine AgonistMemory disorder
The treatment of learning, memory, and age-related memory disorders includes administration of a nicotine antagonist. The preferred nicotine antagonists are mecamylamine, a mecamylamine analog, or a mecamylamine stereoisomer. The effective amount of the nicotine antagonist is 0.005–1.00 mg / kg / day. Alternatively, the method utilizes a partial nicotine agonist.
Owner:SOUTH FLORIDA UNIVESITY OF
Methods for the treatment of respiratory depression
InactiveUS20110003835A1Stable baselineIncrease amplitudeBiocideNervous disorderSIDS - Sudden infant death syndromeCentral sleep apnea
This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stoke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning, hi a particular aspect, the invention relates to bicyclic amide compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.
Owner:CORTEX PHARMA
Multiple lead method for deep brain stimulation
New methods for deep brain stimulation (DBS) surgery using two or more electrical leads are provided. The methods are useful for treating a wide variety of brain-associated disorders including movement-related disorders, psychiatric disorders, metabolic / eating disorders, memory disorders, and pain. Methods featuring stimulation of distinct target areas of a subject's brain, such as the thalamic ventralis intermedius (VIM) and the ventralis oralis (VOA / VOP) using multiple electrical leads for treatment of tremor provide superior clinical outcomes to stimulation with single leads implanted in these target areas.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Construction process of Alzhemer's disease rat animal model
The present invention provides method of constructing Alzhemer's disease (AD) rat animal model through injecting wortmanin as phosphatidylinositol 3 kinase inhibitor and GF-109203X as protein kinase C inhibitor into rat lateral ventricle simultaneously. The method can induce AD-like abnormal excessive phosphorylation of hippocampal skelemin and neurofibrillary tangle-like pathologic changes and constitute rat animal model with co-existed learning and memory disorder. The model may be used in screening medicine for treating Alzhemer's disease and in the research of the internal relation between protein kinase and AD pathogenesis.
Owner:华中科技大学同济医学院
Medicament for preventing and treating senile dementia
ActiveCN104479027AEasy Inducible Expression PuritySuitable for intravenous injectionNervous disorderPeptide/protein ingredientsMicrotubule associated protein tauMemory disorder
The invention discloses a small molecular polypeptide TAT-siP-PTPN1-HA and application thereof in preparation of a medicament for treating or preventing senile dementia. An artificially synthesized TAT protein transduction structural domain and an siP-PTPN1-HA fusion protein polypeptide TAT-siP-PTPN1-HA are used, TAT can carry the siP-PTPN1-HA protein polypeptide to pass through a blood-brain carrier via blood to be absorbed by neurons, and by applying the small molecular polypeptide TAT-siP-PTPN1-HA to an in-vivo senile dementia model, the biological action of blocking the binding of miR-124 and protein tyrosine phosphatase, non-receptor type 1, PTPN1 3'-non-coding sequence (3'-untranslated region, 3'-UTR) can be effectively realized, the expression of PTPN1 is further effectively reversed, excessive phosphorylation of microtube-associated protein tau and amyloid protein deposition, as well as animal learning and memory disorders represented by an senile dementia model animal are improved, and a new direction is provided for further development of the medicaments for clinical treatment of senile dementia.
Owner:HUAZHONG UNIV OF SCI & TECH
Methods for the protection of memory and cognition
InactiveUS20050004104A1Function increaseSlowing or reducing cognitive impairment or memory lossBiocideNervous disorderMemory retentionAmnesia
The invention features certain compounds useful in the treatment of memory disorders, i.e., they reduce or delay memory loss or they enhance memory retention. Because certain of the compounds do not substantially inhibit either COX-1 or COX-2 at therapeutically relevant doses, these compounds are far less likely to cause gastrointestinal ulceration than is indomethacin, which is known to inhibit both COX-1 and COX-2. Certain of the compounds inhibit the activity of DAO at therapeutically relevant doses. Among the memory disorders that can be treated are AD, mild cognitive impairment (MCI; a common precursor to AD), and memory loss or cognitive impairment associated with vascular dementias, amnesia, dementia, AIDS dementia, Huntington's Disease, hydrocephalus, depression, Pick's Disease, Creutzfeldt-Jakob Syndrome, electroconvulsive therapy, or Parkinson's Disease.
Owner:IRONWOOD PHARMA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com